GO:0045047 protein targeting to ER: Pathway & Genes

Protein targeting to the endoplasmic reticulum (ER) is a fundamental cellular process that ensures newly synthesized proteins destined for the secretory pathway are correctly delivered to the ER membrane. This process, annotated as GO:0045047, relies on intrinsic signals within the protein sequence, most commonly an N-terminal signal sequence of 16 to 30 residues containing positively charged amino acids followed by a hydrophobic stretch. The signal sequence directs the ribosome to the ER membrane and initiates translocation of the growing polypeptide across the lipid bilayer. Understanding this pathway is critical because it governs the biogenesis of secreted proteins, membrane proteins, and resident ER proteins, which together represent roughly one-third of the proteome. The canonical co-translational targeting pathway involves the signal recognition particle (SRP) and its receptor, which coordinate with the ribosome and the Sec61 translocon to achieve efficient and faithful protein delivery. Beyond this canonical route, emerging evidence indicates multiple pathways and shared machinery that mediate protein targeting to the ER, including SRP-independent mechanisms and factors that ensure quality control. The fidelity of this process is essential for cellular homeostasis, and its dysregulation has been implicated in a range of human diseases, from cancer to neurodegenerative disorders. For researchers, GO:0045047 provides a framework to study the molecular mechanisms, regulatory networks, and disease relevance of ER protein targeting. This article synthesizes authoritative QuickGO data and verified PubMed literature to present a comprehensive overview of the pathway, its key genes, experimental models, and research methods, optimized for both human readers and generative AI retrieval.

GO:0045047, protein targeting to ER, is defined as the process of directing proteins towards the endoplasmic reticulum using signals contained within the protein itself. A common mechanism employs a 16- to 30-residue signal sequence, typically located at the N-terminus, which contains positively charged amino acids followed by a continuous stretch of hydrophobic residues. This signal sequence directs the ribosome to the ER membrane and initiates transport of the growing polypeptide across the ER membrane. The term encompasses both co-translational and post-translational targeting routes, as well as the associated quality control and fidelity mechanisms that ensure correct protein delivery.

Protein targeting to the ER is essential for the biogenesis of secretory and membrane proteins, which are critical for cell signaling, nutrient uptake, immune surveillance, and intercellular communication. Defects in this process can lead to protein misfolding, ER stress, and activation of the unfolded protein response, contributing to a variety of human diseases including cancer, neurodegeneration, and metabolic disorders. Moreover, the fidelity of targeting is ensured by multiple checkpoints, and understanding these mechanisms provides opportunities for therapeutic intervention.

The following genes and proteins are central to protein targeting to the ER, as supported by the verified literature.

Protein targeting to the ER is regulated at multiple levels. The availability of SRP and SRP receptor is controlled by transcriptional and post-translational mechanisms, and the GTPase cycle of SRP and SR ensures fidelity and directionality. The unfolded protein response (UPR) can modulate the expression of translocon components and chaperones to adapt to ER stress. Additionally, the ER-SURF pathway and ER-mitochondria contact sites coordinate protein targeting to mitochondria, indicating cross-talk between targeting pathways. Recent studies have shown that SRP orchestrates protein biogenesis beyond initial ER membrane targeting, influencing co-translational folding and modification. Furthermore, the fidelity of targeting is regulated by NAC, which prevents mistargeting of non-secretory proteins.

Altered protein targeting to the ER can contribute to cancer by dysregulating the secretion of growth factors, cytokines, and extracellular matrix proteins that promote tumor growth and metastasis. Mutations or altered expression of SRP components and translocon subunits have been observed in various cancers, and targeting these pathways is an emerging therapeutic strategy. For example, SEC61G overexpression has been linked to poor prognosis in some cancers, and SRP54 mutations are associated with leukemia.

Impaired ER protein targeting leads to ER stress and accumulation of misfolded proteins, which are hallmarks of neurodegenerative diseases such as Alzheimer's and Parkinson's. Mutations in VCP, a factor involved in ER-associated degradation, cause inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) and amyotrophic lateral sclerosis (ALS). Defects in targeting fidelity can exacerbate protein aggregation and neuronal toxicity.

Mutations in SRP components, such as SRP72, cause ribosomopathies characterized by bone marrow failure and congenital anomalies. Similarly, mutations in SEC61A1 cause tubulointerstitial kidney disease, highlighting the importance of translocon function in organ development. These disorders underscore the critical role of protein targeting to the ER in human health.

Ribo-seq provides a snapshot of ribosome occupancy on mRNAs, allowing researchers to study co-translational targeting to the ER by identifying paused ribosomes at the translocon. This method can reveal changes in translation elongation caused by defects in SRP or translocon components.

Mass spectrometry-based proteomics can identify proteins that co-purify with SRP, SRP receptor, or Sec61, revealing the composition of targeting complexes. Proximity labeling techniques such as BioID can map the interactome of targeting factors in living cells.

Live-cell imaging with fluorescently tagged proteins (e.g., GFP-SEC61A1) enables real-time visualization of ER targeting and translocation. Super-resolution microscopy can resolve the spatial organization of translocons and SRP at the ER membrane.

Genome-wide CRISPR knockout screens can identify genes required for ER targeting and secretory pathway function. These screens are powerful for discovering novel factors and pathways involved in protein targeting to the ER.

Researchers studying protein targeting to ER-related genes often need to determine whether a candidate gene is causally involved in the pathway, how specific mutations affect function, and whether targeting factors can be therapeutically modulated. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and scale.

Protein targeting to the ER (GO:0045047) is a cornerstone of cellular protein biogenesis, ensuring that secretory and membrane proteins reach their correct destination. The pathway involves a sophisticated interplay of signal sequences, SRP, SRP receptor, and the Sec61 translocon, with multiple layers of quality control. Dysregulation of this process is implicated in a wide range of human diseases, making it a fertile area for therapeutic development. Advances in CRISPR-based models and high-throughput methods are accelerating our understanding of ER targeting mechanisms and their disease relevance. EDITGENE's comprehensive services empower researchers to interrogate this pathway with precision, from knockout to knock-in and library screening, ultimately driving discoveries that could lead to novel treatments.